146 related articles for article (PubMed ID: 32518611)
1. Adherence to National Comprehensive Cancer Network Guidelines for
Bobbili P; Olufade T; DerSarkissian M; Shenolikar R; Yu H; Duh MS; Tung N
Hered Cancer Clin Pract; 2020; 18():13. PubMed ID: 32518611
[TBL] [Abstract][Full Text] [Related]
2. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.
Beck AC; Yuan H; Liao J; Imperiale P; Shipley K; Erdahl LM; Sugg SL; Weigel RJ; Lizarraga IM
Am J Surg; 2020 Jan; 219(1):145-149. PubMed ID: 31255259
[TBL] [Abstract][Full Text] [Related]
3. Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.
Lee SS; Rajeev P; Finning S; Oh C; Pothuri B
Gynecol Oncol; 2023 Mar; 170():32-37. PubMed ID: 36610379
[TBL] [Abstract][Full Text] [Related]
4. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals.
Stuckey A; Febbraro T; Laprise J; Wilbur JS; Lopes V; Robison K
Am J Clin Oncol; 2016 Aug; 39(4):363-7. PubMed ID: 24710121
[TBL] [Abstract][Full Text] [Related]
5. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
Chun DS; Berse B; Venne VL; DuVall SL; Filipski KK; Kelley MJ; Meyer LJ; Icardi MS; Lynch JA
Fam Cancer; 2017 Jan; 16(1):41-49. PubMed ID: 27589855
[TBL] [Abstract][Full Text] [Related]
6.
Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
[TBL] [Abstract][Full Text] [Related]
7. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
Barcenas CH; Shafaee MN; Sinha AK; Raghavendra A; Saigal B; Murthy RK; Woodson AH; Arun B
J Natl Compr Canc Netw; 2018 May; 16(5):518-524. PubMed ID: 29752326
[No Abstract] [Full Text] [Related]
8. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of
Forbes C; Fayter D; de Kock S; Quek RG
Cancer Manag Res; 2019; 11():2321-2337. PubMed ID: 30962720
[TBL] [Abstract][Full Text] [Related]
11. Integration of Genetic Testing and Counseling in Patients With Breast Cancer in a Large, Multisite Community-Based Practice.
Mendenhall MA; Guinigundo A; Davies D; Ward P; Drosick DR; Waterhouse DM
JCO Oncol Pract; 2024 Feb; 20(2):262-267. PubMed ID: 37369093
[TBL] [Abstract][Full Text] [Related]
12. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
[TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of Universal
Emborgo TS; Saporito D; Muse KI; Barrera AMG; Litton JK; Lu KH; Arun BK
JNCI Cancer Spectr; 2020 Apr; 4(2):pkaa002. PubMed ID: 32211581
[TBL] [Abstract][Full Text] [Related]
14. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
16. Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives.
Abdel-Razeq H; Tamimi F; Abujamous L; Abdel-Razeq R; Abunasser M; Edaily S; Abdulelah H; Khashabeh RA; Bater R
Front Oncol; 2022; 12():673094. PubMed ID: 35402282
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of early-stage breast cancer patients that meet indications for
Xiang H; Xin L; Liu Q; Zhang H; Zhang S; Ye J; Cheng Y; Li T; Liu Y; Xu L
Chin J Cancer Res; 2020 Apr; 32(2):163-174. PubMed ID: 32410794
[TBL] [Abstract][Full Text] [Related]
18. BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.
Toss A; Molinaro E; Venturelli M; Domati F; Marcheselli L; Piana S; Barbieri E; Grandi G; Piombino C; Marchi I; Tenedini E; Tagliafico E; Tazzioli G; Cortesi L
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429297
[TBL] [Abstract][Full Text] [Related]
19. Demographic Barriers for Genetic Testing in High-Risk Breast Cancer Patients in the Northern Michigan Area.
Hebert D; Pacheco F; WintonLi L; Taj A
Cureus; 2022 Mar; 14(3):e22966. PubMed ID: 35411261
[TBL] [Abstract][Full Text] [Related]
20. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
